Skip to content

Presentations of Hypertrophic Cardiomyopathy on Myocardial Perfusion Imaging

Presentations of Hypertrophic Cardiomyopathy on Myocardial Perfusion Imaging

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03150342
Enrollment
100
Registered
2017-05-12
Start date
2017-05-08
Completion date
2018-06-30
Last updated
2017-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertrophic Cardiomyopathy, Myocardial Perfusion Imaging

Keywords

CZT scanner, myocardial perfusion imaging, Hypertrophic Cardiomyopathy

Brief summary

Chest pain and myocardial ischemia are prevailing features in patients with hypertrophic cardiomyopathy (HCM). Recently introduced single-photon emission computed tomography (SPECT) cameras with solid-state cadmium-zinc-telluride (CZT) detectors have been shown to decrease imaging time and improved the imaging quality of gated myocardial perfusion imaging (MPI). The investigators also correlate the MPI parameters with echocardiographic parameters. This study is to examine the spatial distribution of stress perfusion abnormalities and tissue injury in patients with HCM using a CZT SPECT camera.

Detailed description

The investigators will retrospectively evaluate myocardial perfusion patterns and cardiac function with Thallium (Tl)-201 gated dipyridamole MPI in patients with clinical diagnosis of HCM and patent coronary angiography between January 2013 and October 2016. The inclusion criteria included a spade-like configuration on left ventriculogram, or echocardiographic findings suggestive of HCM. The participants will be then divided into the following three groups: apical, concentric and septal forms. Regional perfusion would be analyzed using a 17-segment model from 0-4 degree (0=normal, to 4=absent perfusion); and summed stress score (SSS), summed rest score (SRS) and summed difference score (SDS) were calculated. Gated SPECT would be processed by quantitative gated SPECT (QGS) software (Cedars-Sinai Medical Center, Los Angeles, CA, USA) and ejection fraction phase analysis. Diastolic parameters would be also acquired by Doppler echocardiography, and correlated with MPI parameters.

Interventions

DIAGNOSTIC_TESTmyocardial perfusion imaging

dipyridamole-stressed MPI scan using thallium-201

Sponsors

Far Eastern Memorial Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* clinical diagnosis of HCM and patent coronary angiography between January 2013 and October 2016.

Exclusion criteria

* patient with prior myocardial ischemia, conduction abnormality, valvular disease or other cardiomyopathy

Design outcomes

Primary

MeasureTime frameDescription
MPI resultsJanuary 2013 and October 2016.including perfusion abnormalities, and ejection fraction phase analysis results

Countries

Taiwan

Contacts

Primary ContactSzu-Ying Tsai, MD
dorissyt@mail.femh.org.tw+886289227000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026